- Home
- MYFW vs PLX Comparison
MYFW vs PLX Comparison
Compare MYFW & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYFW | PLX |
|---|---|---|
| Founded | 2002 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.6M | 230.0M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MYFW | PLX |
|---|---|---|
| Price | $24.49 | $2.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $24.25 | $12.00 |
| AVG Volume (30 Days) | 19.7K | ★ 1.1M |
| Earning Date | 04-23-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.02 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $96,914,000.00 | $52,744,000.00 |
| Revenue This Year | $20.48 | $37.52 |
| Revenue Next Year | $9.70 | $1.25 |
| P/E Ratio | $18.21 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $17.55 | $1.34 |
| 52 Week High | $28.00 | $3.19 |
Technical Indicators
Market Signals| Indicator | MYFW | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 31.90 |
| Support Level | $22.09 | $2.03 |
| Resistance Level | $26.27 | $2.14 |
| Average True Range (ATR) | 0.75 | 0.13 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 64.37 | 6.44 |
Price Performance
Historical ComparisonAbout MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.